49 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
biotechnology industry and society at large.
EXECUTIVE AND DIRECTOR COMPENSATION
Executive Officers
Certain information regarding our executive
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
, who are not suitable candidates for standard intensive chemotherapy.
At the 62nd American Society of Hematology Annual Meeting and Exposition held
8-K
EX-99.2
r2ue86btkitjiyt9v
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.1
65pf7h4czt jh4
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
wicbeq6lbn
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
ey4q ipdogomuo3a57
12 Dec 22
Regulation FD Disclosure
7:48am
425
duzem6
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
9jctvtrqnr7v6 ruak
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am